American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

NuCana plc (NCNA)

$1.29 -3.01% NASDAQ: NCNA · 15-min delayed

Public · NASDAQ: NCNA
12 employees

Visit website Follow

$8.1MMarket cap

12Employees

NCNANASDAQ

2017IPO

About NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: NCNA
Employees: 12
IPO date: Sep 28, 2017
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: NCNA Nasdaq
SEC CIK: 1709626
SIC: 2834 Pharmaceutical Preparations

Embed this company’s badge

Show NuCana plc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/nucana-plc/"><img src="https://americancompanies.com/badge/nucana-plc.svg" alt="NuCana plc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow NuCana plc and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Market cap: $8.1M

NASDAQ: NCNA

$1.29 -3.01%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.24 $20.00

52-week range

Market cap: $8.1M
Shares outstanding: 6.3M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Sep 28, 2017

NuCana plc (NCNA) Stock Price

Trading 94% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review NuCana plc.

Write a review

Newsroom

News about NuCana plc

NuCana Appoints Theresa Bruce as Chief Operating Officer GlobeNewswire Inc. · 2026-01-06 · positive NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma GlobeNewswire Inc. · 2025-12-10 · positive NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China GlobeNewswire Inc. · 2025-11-05 · positive NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025 GlobeNewswire Inc. · 2025-09-03 · positive NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update GlobeNewswire Inc. · 2024-08-15 · neutral NuCana to Present at the Jefferies Global Healthcare Conference GlobeNewswire Inc. · 2024-05-30

News & sentiment via Polygon.io

FAQ

NuCana plc: frequently asked questions

Is NuCana plc an American company?

NuCana plc is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is NuCana plc publicly traded?

Yes — NuCana plc is a publicly traded company. Its stock trades under the ticker symbol NCNA on the NASDAQ.

What does NuCana plc do?

NuCana plc is an American Pharmaceuticals company in the Health & Beauty sector.

Explore